Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

NCT02437786 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinoconjunctivitis

Interventions

DRUG: GRAZAX

Sponsor

ALK-Abelló A/S